IMOJEV Overview

  • Status
  • Acquired/​Merged

  • Latest Deal Type
  • Asset Purch.

  • Financing Rounds
  • 1

IMOJEV General Information

Description

Japanese encephalitis vaccine intended for adults and children.

Contact Information

Ownership Status
Acquired/Merged
Financing Status
Corporate Backed or Acquired
Corporate Office
  • Paris
  • France
Primary Industry
Buildings and Property
Other Industries
Drug Discovery
Acquirer
Corporate Office
  • Paris
  • France

Want detailed data on 11M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

IMOJEV Valuation & Funding

Deal Type Date Amount Valuation/
EBITDA
Post-Val Status Debt

This information is available in the PitchBook Platform. To explore IMOJEV‘s full profile, request access.

Request a free trial

IMOJEV Former Investors

Investor Name Investor Type Holding Investor Since Participating Rounds Contact Info

This information is available in the PitchBook Platform. To explore IMOJEV‘s full profile, request access.

Request a free trial

IMOJEV FAQs

  • Where is IMOJEV headquartered?

    IMOJEV is headquartered in Paris, France.

  • What industry is IMOJEV in?

    IMOJEV’s primary industry is Buildings and Property.

  • Is IMOJEV a private or public company?

    IMOJEV is a Private company.

  • What is IMOJEV’s current revenue?

    The current revenue for IMOJEV is .

  • Who are IMOJEV’s investors?

    Sanofi has invested in IMOJEV.

  • When was IMOJEV acquired?

    IMOJEV was acquired on 30-Nov-2022.

  • Who acquired IMOJEV?

    IMOJEV was acquired by Substipharm.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read more
  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process